Polyalkylene polymer compounds and uses thereof
AssigneeBiogen Idec MA Inc.
InventorsKoChung Lin, R. Blake Pepinsky, Ling Ling Chen, Donna M. Hess, Edward Y. Lin, Russell C. Petter, Darren P. Baker
Life of this patent
Estimating the term…
Abstract
The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.
Claims3
A method of treating a patient having an interferon-susceptible viral infection, comprising administering to the patient an effective amount of a composition having the structure according to the formula
- wherein E is hydrogen, a straight- or branched-chain C1 to C20 alkyl group, or a detectable label;
- a is an integer from 4 to 10,000;
- each Z and Z′ is independently hydrogen, a straight- or branched-chain, saturated or unsaturated C1 to C20 alkyl or heteroalkyl group, C3 to C8 saturated or unsaturated cyclic alkyl or cyclic heteroalkyl, a substituted or unsubstituted aryl or heteroaryl group or a substituted or unsubstituted alkaryl wherein the alkyl is a C1 to C20 saturated or unsaturated alkyl or heteroalkaryl group, wherein in the substituted groups the substitution is selected from the group consisting of halogen, hydroxyl, carbonyl, carboxylate, ester, formyl, acyl, thiocarbonyl, thioester, thioacetate, thioformate, alkoxyl, phosphoryl, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, an aromatic moiety, a heteroaromatic moiety, imino, silyl, ether, and alkylthio, provided that at least one Z or Z′ is not hydrogen;
- R* is a linking moiety formed from the reaction of a moiety selected from the group consisting of aldehyde, aldehyde hydrate, and acetal, with B, wherein B is a biologically-active molecule or precursor thereof that comprises interferon-beta-1a (IFN-β-1a);
- each n is 0 or an integer from 1 to 5;
- and
- p is 1, 2, or 3.
A method of treating multiple sclerosis in a patient suffering therefrom, comprising administering to said patient an effective amount of a composition having the structure according to the formula
- wherein E is hydrogen, a straight- or branched-chain C1 to C20 alkyl group, or a detectable label;
- a is an integer from 4 to 10,000;
- each Z and Z′ is independently hydrogen, a straight- or branched-chain, saturated or unsaturated C1 to C20 alkyl or heteroalkyl group, C3 to C8 saturated or unsaturated cyclic alkyl or cyclic heteroalkyl, a substituted or unsubstituted aryl or heteroaryl group or a substituted or unsubstituted alkaryl wherein the alkyl is a C1 to C20 saturated or unsaturated alkyl or heteroalkaryl group, wherein in the substituted groups the substitution is selected from the group consisting of halogen, hydroxyl, carbonyl, carboxylate, ester, formyl, acyl, thiocarbonyl, thioester, thioacetate, thioformate, alkoxyl, phosphoryl, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, an aromatic moiety, a heteroaromatic moiety, imino, silyl, ether, and alkylthio, provided that at least one Z or Z′ is not hydrogen;
- R* is a linking moiety formed from the reaction of a moiety selected from the group consisting of aldehyde, aldehyde hydrate, and acetal, with B, wherein B is a biologically-active molecule or precursor thereof that comprises interferon-beta-1a (IFN-β-1a);
- each n is 0 or an integer from 1 to 5;
- and
- p is 1, 2, or 3.
Dependencies are inferred from the claim text.